Harrys A. Torres

6.1k total citations
114 papers, 3.6k citations indexed

About

Harrys A. Torres is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Harrys A. Torres has authored 114 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Epidemiology, 63 papers in Hepatology and 35 papers in Infectious Diseases. Recurrent topics in Harrys A. Torres's work include Hepatitis C virus research (61 papers), Hepatitis B Virus Studies (29 papers) and Liver Disease Diagnosis and Treatment (27 papers). Harrys A. Torres is often cited by papers focused on Hepatitis C virus research (61 papers), Hepatitis B Virus Studies (29 papers) and Liver Disease Diagnosis and Treatment (27 papers). Harrys A. Torres collaborates with scholars based in United States, Egypt and France. Harrys A. Torres's co-authors include Dimitrios P. Kontoyiannis, Issam Raad, Ray Hachem, Parag Mahale, Roy F. Chemaly, Gerald P. Bodey, Russell E. Lewis, Marta Davila, Ying Jiang and Gustavo Rivero and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Harrys A. Torres

108 papers receiving 3.5k citations

Peers

Countries citing papers authored by Harrys A. Torres

Since Specialization

Citations

This map shows the geographic impact of Harrys A. Torres's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harrys A. Torres with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harrys A. Torres more than expected).

Fields of papers citing papers by Harrys A. Torres

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harrys A. Torres. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harrys A. Torres. The network helps show where Harrys A. Torres may publish in the future.

Co-authorship network of co-authors of Harrys A. Torres

This figure shows the co-authorship network connecting the top 25 collaborators of Harrys A. Torres. A scholar is included among the top collaborators of Harrys A. Torres based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harrys A. Torres. Harrys A. Torres is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Direct‐Acting Antivirals Induce Lymphoproliferative Disease Response in HCV‐Infected Patients With Indolent B‐Cell Non‐Hodgkin’s Lymphoma: A Prospective Observational Study 2025 ·Hematological Oncology ·Mónica George, (unknown), Sairah Ahmed, Sheeba K. Thomas, Ying Jiang, Krina K. Patel, Harrys A. Torres	1
2	Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors 2024 ·SHILAP Revista de lepidopterología ·(unknown), Vincent Mallet, Harrys A. Torres	3
3	Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center 2024 ·Journal of the National Comprehensive Cancer Network ·Harrys A. Torres, (unknown), (unknown), Jessica Hwang, (unknown), (unknown), Ernest T. Hawk, Bruno Granwehr, (unknown), Anita K. Ying	1
4	Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors 2023 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Sairah Ahmed, Sheeba K. Thomas, (unknown), (unknown), Luis Fayad, William G. Wierda, Fareed Khawaja, Harrys A. Torres	7
5	False-Reactive Fourth-Generation Human Immunodeficiency Virus Testing in Cancer Patients 2023 ·Clinical Infectious Diseases ·Chiayu Q. Chiu, (unknown), Micah M. Bhatti, (unknown), Bruno Granwehr, Harrys A. Torres	1
6	Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies 2022 ·Clinical Microbiology and Infection ·(unknown), Harrys A. Torres	33
7	Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study 2020 ·Supportive Care in Cancer ·Harrys A. Torres, Anna S. Lok, María E. Suarez‐Almazor, Carla L. Warneke, Ahmed O. Kaseb, Ethan Miller, Erich M. Sturgis, (unknown), (unknown), Sairah Ahmed, Alessandra Ferrajoli, Felipe Samaniego, Ernest T. Hawk, Jessica Hwang	1
8	Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct‐acting antivirals—A prospective study 2019 ·JGH Open ·(unknown), (unknown), Jeff Hosry, (unknown), Harrys A. Torres	1
9	Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Alexandre Malek, Yago Nieto, Ariel D. Szvalb, (unknown), Mehnaz A. Shafi, Jessica Hwang, Issam Raad, Harrys A. Torres	10
10	Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer 2017 ·Cancer ·Minas P. Economides, Moran Amit, Parag Mahale, Jeff Hosry, Ying Jiang, Uddalak Bharadwaj, Erich M. Sturgis, Harrys A. Torres	6
11	Clinicopathologic characteristics and outcomes of transformed diffuse large B‐cell lymphoma in hepatitis C virus‐infected patients 2017 ·International Journal of Cancer ·Jeff Hosry, Roberto N. Miranda, Felipe Samaniego, Minas P. Economides, Harrys A. Torres	13
12	The oncologic burden of hepatitis C virus infection: A clinical perspective 2017 ·CA A Cancer Journal for Clinicians ·Harrys A. Torres, Terri Lynn Shigle, Nassim Hammoudi, J. T. Link, Felipe Samaniego, Ahmed O. Kaseb, Vincent Mallet	67
13	How I treat hepatitis C virus infection in patients with hematologic malignancies 2016 ·Blood ·Harrys A. Torres, George B. McDonald	22
14	Association Between Hepatitis C Virus and Head and Neck Cancers 2016 ·JNCI Journal of the National Cancer Institute ·Parag Mahale, Erich M. Sturgis, David J. Tweardy, Ella Ariza‐Heredia, Harrys A. Torres	50
15	Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma 2015 ·Gastroenterology ·Manal M. Hassan, Reham Abdel‐Wahab, Ahmed O. Kaseb, Ahmed Shalaby, Alexandria T. Phan, Hashem B. El‐Serag, Ernest T. Hawk, J. Morris, Kanwal Raghav, Ju‐Seog Lee, Jean‐Nicolas Vauthey, (unknown), Harrys A. Torres, Christopher I. Amos, Robert A. Wolff, Donghui Li	73
16	Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: A retrospective multicenter study 2012 ·Journal of Clinical Virology ·Harrys A. Torres, Moises I. Nevah, Ben J. Barnett, Parag Mahale, Dimitrios P. Kontoyiannis, Manal M. Hassan, Issam Raad	12
17	Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer 2012 ·Nature Reviews Clinical Oncology ·Harrys A. Torres, Marta Davila	123
18	Viral infection or reactivation in patients during treatment with dasatinib: A call for screening? 2007 ·Leukemia & lymphoma ·Harrys A. Torres, Roy F. Chemaly	7
19	Protothecosis in patients with cancer: case series and literature review 2003 ·Clinical Microbiology and Infection ·Harrys A. Torres, Gerald P. Bodey, Jeffery Tarrand, Dimitrios P. Kontoyiannis	59
20	Open lung biopsy in bone marrow transplant recipients has a poor diagnostic yield for a specific diagnosis 2002 ·Transplant Infectious Disease ·(unknown), Harrys A. Torres, G. Walsh, Richard E. Champlin, Dimitrios P. Kontoyiannis, (unknown), (unknown), (unknown), (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact